Web Results

caselaw.findlaw.com/us-supreme-court/09-152.html

BRUESEWITZ ET AL. v. WYETH LLC, FKA WYETH, INC., ET AL., (2011). No. 09- 152. Argued: October 12, 2010 Decided: February 22, 2011. The National Childhood Vaccine Injury Act of 1986 (NCVIA or Act) created a no-fault compensation program to stabilize a vaccine market adversely affected by an increase in ...

www.oyez.org/cases/2010/09-152

Oct 12, 2010 ... Bruesewitz v. Wyeth Inc. ... Respondent. Wyeth, Inc., fka Wyeth Laboratories, et al . ... defective design. A federal judge dismissed the lawsuit, ruling that the National Childhood Vaccine Injury Act protected Wyeth from lawsuits over vaccine injury claims. The U.S. Court of Appeals for the 3rd Circuit affirmed.

www.floridatrialattorneys.net/attorneys/mitchell-lloyd-feldman

Most recently, in March, 2016, Mr. Feldman, along with co-counsel, prevailed on a multiple Plaintiff Florida Minimum Wage and FLSA jury trial case in the Middle District of Florida, Jacksonville Division styled: Kubiak, et al v. Salt Water Cowboy , Inc. et al, Case No.: 3:12-CV-1306-J-34JRK. The Jury awarded 100% of the ...

link.springer.com/content/pdf/10.1007/s11481-008-9135-1.pdf

Nov 26, 2008 ... Ransohoff 2004; Banisadr et al. 2005; Rebenko-Moll et al. 2006; Ubogu et al. 2006; Li and Ransohoff 2008). One of the most investigated and disease- associated chemokine is monocyte chemoattractant protein-1 (MCP-1), which plays a pivotal role in the recruitment of mononuclear phagocytes.

link.springer.com/content/pdf/10.1007/BF01296725.pdf

was reduced with the administration of three enzyme tablets with meals (73 vs 29 g/24 hr). ... 1.9 mEq/ml (Amphojel, Wyeth Laboratories, Philadel- ..... Regan et al considered antacids to be ineffective because of either (1) failure to provide sufficient protection. TABLE 3. Acid Output (mEq/hr). Basal. Maximum*. 1:4. 8.0. 2.4.

www.ippractice.ca/litigation-statistics/intellectual-property-proceedings-in-federal-court-for-2004

MOUNTAIN CREST LIQUORS INC. AND OTHERS, Trade Mark Infringement, 2004-01-08, Bereskin & Parr LLP; BERESKIN, DANIEL R;. T-41-04, ASTRAZENECA AB v. THE REGISTRAR OF TRADE-MARKS ET AL, Trade Mark – Appeal of a decision of the Registrar, 2004-01-09, Smart & Biggar; GAIKIS, GUNARS A;.

www.atsjournals.org/doi/pdf/10.1164/rccm.200901-0159PP

Jan 30, 2009 ... Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterized by both small airway and parenchymal abnor- malities. There is increasing evidence to suggest that these two mor- phologic phenotypes, although related, may have different clinical presentations, prognosis, and ...

onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2006.04315.x/full

Nov 7, 2006 ... Moreover, microglial activation occurs throughout the disease course, suggesting that it contributes to nigrostriatal degeneration (Vila et al. ... 1% penicillin/ streptomycin) containing 2 µg/mL macrophage colony stimulating factor (MCSF), a generous gift from Wyeth Pharmaceuticals (Cambridge, MA, USA).

www.plainsite.org/judges/missouri-eastern-district-court/rodney-w-sippel

Space, Sort Descending Date Filed · Case Number · Title, Space. 9/8/2017 · 4:17- cv-02377 · Frazier v. State Farm Fire & Casualty Company et al ... 7/29/2016 · 4: 16-cv-01244 · Dubuque v. Air Force Office of Special Investigations et al ... 6/13/ 2016 · 4:16-cv-00839 · Griffin v. RightChoice Managed Care, Inc. et al ...